Removing the Need to Open New Ones

AI-powered Platform helps sponsors and CROs hit enrollment targets faster by surfacing qualified patients near their active sites

TrialWire today shared a key benefit of its patient-identification platform that helps clinical trial sponsors and contract research organizations (CROs) find eligible patients missed by advertising or site databases. TrialWire can surface these patients saving time and money standing up new sites.

When enrollment falls behind, the industry’s default reflex is to add sites. But every new site carries meaningful regulatory startup, contracting, training, and activation costs and a significant share of newly opened sites enroll few patients, or none at all. The result is a slower, more expensive path to database lock with no guarantee it closes the enrollment gap.

TrialWire takes a different approach. Its proprietary AI-powered algorithms surface patients who already meet a study’s eligibility criteria but were never screened, flagged, or referred. Sites keep their existing patients; sponsors keep their existing footprint; and enrollment accelerates without the cost and delay of expansion.

TrialWire operates within [HIPAA / GDPR-compliant, privacy-preserving workflows, so patient data never leaves the Platform’s site portal environment.

The platform is available now for sponsors, CROs, and research sites. To learn more or request a demo, visit www.trialwire.ai

About TrialWire

TrialWire is a clinical trial technology company that helps sponsors, CROs, and research sites accelerate patient recruitment by finding eligible patients and AI-screening them to study I/E criteria then sharing in a secure Portal for site teams to progress them to enrollment.

TrialWire is the fastest and most accurate find, screen, and enroll solution built with enterprise level security on Salesforce Health Cloud.